Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 37.00
Ask: 39.00
Change: -1.00 (-2.56%)
Spread: 2.00 (5.405%)
Open: 39.00
High: 39.00
Low: 38.00
Prev. Close: 39.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum Cautiously Optimistic As It Posts Widened First Half Loss

Wed, 25th Feb 2015 11:32

LONDON (Alliance News) - Sareum Holdings PLC Wednesday expressed "cautious optimism" for its future as it has reached a "critical stage" in its drug development programmes, although increased investment in its research programme caused its pretax loss to widen in the first half of its financial year.

The company posted a pretax loss of GBP749,000 for the six months to end-December, compared with a pretax loss of GBP375,000 a year earlier, which it attributed to increased investment in its research programme as they reach more advanced stages of development. It is not yet producing any revenue.

The specialist cancer drug business said its Checkpoint Kinase 1 programme, targeting lung, pancreatic, and other cancers, is nearing completion of toxicology studies. After these results it will submit an application to begin a Phase I clinical trial, which it expects to take place in the first half of its next financial year to end-June 2016, and will trigger a financial commitment of up to GBP795,500 from Sareum.

Sareum said it was also making good progress with its TYK3 and Aurora+FLT3 development programmes, having secured several key patents in some markets.

The company said that the next phase of its business could be "transformative in terms of the company reaching its goal of delivering a clinical-stage research programme. Later stage programmes achieve higher asset values and, while there is always risk with any drug development, there is also significant potential upside," the company said.

It is continuing to talk to licence partners on potential commercialisation of its compounds, and said that to maintain its product pipeline it is continuing to investigate sources of new research opportunities.

"We are extremely pleased with the progress that has been made in the last six months across all our programmes, and CHK1 in particular which is reaching a crucial phase of development as it nears its first in-human trials," said Chief Executive Officer Tim Mitchell in a statement.

Still shares in Sareum are trading down 16.7% at 0.375 pence Wednesday morning, its lowest level since February 6.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.